Es gab 50 kürzliche Insider-Transaktionen für Arbutus Biopharma Corporation (ABUS), darunter 31 Käufe und 10 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $16.12M und die gesamten Insider-Verkäufe auf $528.88K.
Bedeutende Insider mit kürzlicher Aktivität umfassen Androski Lindsay, Nguyen Tuan, Sawhney Roger. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — ABUS
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2026-02-02 |
Androski Lindsay |
President and CEO |
RSU-Zuteilung |
28,000 |
- |
- |
28,000 |
| 2026-02-02 |
Nguyen Tuan |
Chief Financial Officer |
RSU-Zuteilung |
73,500 |
- |
- |
73,500 |
| 2025-08-04 |
Sawhney Roger |
Director |
Unbekannt |
- |
- |
- |
- |
| 2025-08-04 |
Sawhney Roger |
Director |
RSU-Zuteilung |
157,600 |
$3.34 |
$526.38K |
157,600 |
| 2025-03-31 |
Nguyen Tuan |
Chief Financial Officer |
RSU-Zuteilung |
750,000 |
$3.50 |
$2.63M |
750,000 |
| 2025-03-31 |
Nguyen Tuan |
Chief Financial Officer |
RSU-Zuteilung |
750,000 |
$3.49 |
$2.62M |
750,000 |
| 2025-03-28 |
Nguyen Tuan |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2025-03-18 |
Beardsley Robert A |
Director |
RSU-Zuteilung |
157,600 |
$3.20 |
$504.32K |
157,600 |
| 2025-03-18 |
Androski Lindsay |
President and CEO |
RSU-Zuteilung |
310,422 |
$3.20 |
$993.35K |
310,422 |
| 2025-03-18 |
Hasija Anuj |
Director |
RSU-Zuteilung |
157,600 |
$3.20 |
$504.32K |
157,600 |
| 2025-02-24 |
Beardsley Robert A |
Director |
Unbekannt |
- |
- |
- |
- |
| 2025-02-24 |
Gline Matthew |
10 Percent Owner |
Unbekannt |
- |
- |
- |
38,847,462 |
| 2025-02-24 |
Androski Lindsay |
President and CEO |
Unbekannt |
- |
- |
- |
- |
| 2025-02-24 |
Hasija Anuj |
Director |
Unbekannt |
- |
- |
- |
- |
| 2025-02-24 |
Bishop Joseph E |
Director |
Unbekannt |
- |
- |
- |
- |
| 2025-02-14 |
Hastings David C |
Chief Financial Officer |
RSU-Zuteilung |
90,100 |
- |
- |
249,824 |
| 2025-02-14 |
Naftzger J. Christopher |
General Counsel and Cco |
RSU-Zuteilung |
54,300 |
- |
- |
140,544 |
| 2025-02-14 |
Mcelhaugh Michael J. |
Interim President & CEO |
RSU-Zuteilung |
718,800 |
$3.29 |
$2.36M |
718,800 |
| 2025-02-14 |
Sims Karen |
Chief Medical Officer |
RSU-Zuteilung |
49,300 |
- |
- |
155,494 |
| 2025-02-04 |
Hastings David C |
Chief Financial Officer |
Informierter Verkauf |
22,183 |
$3.28 |
$72.83K |
159,724 |
| 2025-02-04 |
Naftzger J. Christopher |
General Counsel and Cco |
Informierter Verkauf |
11,333 |
$3.28 |
$37.21K |
86,244 |
| 2025-02-04 |
Mcelhaugh Michael J. |
Interim President & CEO |
Informierter Verkauf |
23,790 |
$3.28 |
$78.1K |
1,481,003 |
| 2025-02-04 |
Sims Karen |
Chief Medical Officer |
Informierter Verkauf |
19,348 |
$3.28 |
$63.52K |
106,194 |
| 2024-08-14 |
Manchester Keith S |
Director |
Optionsausübung (Verkauf) |
54,915 |
$0.56 |
$30.75K |
- |
| 2024-05-23 |
Henriques Richard C Jr |
Director |
RSU-Zuteilung |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Burgess Daniel D |
Director |
RSU-Zuteilung |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Manchester Keith S |
Director |
RSU-Zuteilung |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Meyers James R |
Director |
RSU-Zuteilung |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Torti Frank |
Director |
RSU-Zuteilung |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Rewolinski Melissa |
Director |
RSU-Zuteilung |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-02-02 |
Hastings David C |
Chief Financial Officer |
Informierter Verkauf |
9,593 |
$2.31 |
$22.18K |
181,907 |
| 2024-02-02 |
Sofia Michael J. |
Chief Scientific Officer |
Informierter Verkauf |
9,982 |
$2.31 |
$23.08K |
1,485,121 |
| 2024-02-02 |
Mcelhaugh Michael J. |
Interim President & CEO |
Informierter Verkauf |
10,164 |
$2.31 |
$23.5K |
1,504,793 |
| 2024-02-02 |
Sims Karen |
Chief Medical Officer |
Informierter Verkauf |
4,358 |
$2.31 |
$10.08K |
125,542 |
| 2024-02-01 |
Hastings David C |
Chief Financial Officer |
RSU-Zuteilung |
112,500 |
- |
- |
191,500 |
| 2024-02-01 |
Naftzger J. Christopher |
General Counsel and Cco |
RSU-Zuteilung |
95,100 |
- |
- |
95,100 |
| 2024-02-01 |
Sofia Michael J. |
Chief Scientific Officer |
RSU-Zuteilung |
437,800 |
$2.40 |
$1.05M |
437,800 |
| 2024-02-01 |
Mcelhaugh Michael J. |
Interim President & CEO |
RSU-Zuteilung |
495,100 |
$2.40 |
$1.19M |
495,100 |
| 2024-02-01 |
Sims Karen |
Chief Medical Officer |
RSU-Zuteilung |
101,000 |
- |
- |
129,900 |
| 2023-07-12 |
Rewolinski Melissa |
Director |
Unbekannt |
- |
- |
- |
- |
| 2023-07-12 |
Rewolinski Melissa |
Director |
RSU-Zuteilung |
110,000 |
$2.27 |
$249.7K |
110,000 |
| 2023-07-10 |
Naftzger J. Christopher |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2023-07-10 |
Naftzger J. Christopher |
General Counsel and Cco |
RSU-Zuteilung |
500,000 |
$2.26 |
$1.13M |
500,000 |
| 2023-07-10 |
Sims Karen |
Chief Medical Officer |
Veräußerung |
57,800 |
$2.90 |
$167.62K |
- |
| 2023-07-10 |
Sims Karen |
Chief Medical Officer |
RSU-Zuteilung |
153,640 |
$2.26 |
$347.23K |
153,640 |
| 2023-05-24 |
Henriques Richard C Jr |
Director |
RSU-Zuteilung |
55,000 |
$2.56 |
$140.8K |
55,000 |
| 2023-05-24 |
Burgess Daniel D |
Director |
RSU-Zuteilung |
55,000 |
$2.56 |
$140.8K |
55,000 |
| 2023-05-24 |
Manchester Keith S |
Director |
RSU-Zuteilung |
55,000 |
$2.56 |
$140.8K |
55,000 |
| 2023-05-24 |
Meyers James R |
Director |
RSU-Zuteilung |
55,000 |
$2.56 |
$140.8K |
55,000 |
| 2023-05-24 |
Torti Frank |
Director |
RSU-Zuteilung |
55,000 |
$2.56 |
$140.8K |
55,000 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
